Literature DB >> 8301927

Intermittent versus continuous administration of 1,25-dihydroxyvitamin D3 in experimental renal hyperparathyroidism.

H Reichel1, A Szabo, J Uhl, S Pesian, A Schmutz, H Schmidt-Gayk, E Ritz.   

Abstract

Conflicting results have been reported regarding the efficacy of intermittent versus continuous administration of 1,25(OH)2D3 in renal secondary hyperparathyroidism. To address this issue we examined sham-operated control rats and hyperparathyroid rats with subtotal (5/6) nephrectomy (Nx). The Nx animals (20 to 22 animals per group) were subjected to three treatment protocols: (i) solvent treatment (Nx-solvent); (ii) two i.p. injections of 35 pmol 1,25(OH)2D3 on days 0 and 4 (Nx-bolus); and (iii) continuous infusion of 70 pmol 1,25(OH)2D3 over six days via osmotic minipump (Nx-infusion). All measurements were performed six days after start of treatment. As compared to sham-operated controls, the pre-pro-PTH/beta-actin mRNA ratio was 2.04-fold higher in Nx-solvent. Both modes of administration of 1,25(OH)2D3 resulted in inhibition of PTH mRNA concentrations relative to Nx-solvent. The pre-pro-PTH/beta-actin mRNA ratio was, however, significantly lower (P < 0.05) in Nx-bolus than in Nx-infusion (Nx-bolus 1.26 higher than sham-operated controls; Nx-infusion 1.65 higher than sham-operated controls). Aminoterminal PTH (N-PTH) serum concentrations were higher in Nx-solvent (52 +/- 4 pg/ml) than in sham-operated controls (32 +/- 3 pg/ml, P < 0.01). N-PTH concentrations in Nx-bolus (38 +/- 4 pg/ml) were significantly lower than in Nx-solvent (P < 0.01) and in Nx-infusion (46 +/- 4 pg/ml, P < 0.05). Parathyroid gland weight (microgram/g body wt) was higher in Nx-solvent (1.30 +/- 0.08 pg/ml) than in sham-operated controls (0.79 +/- 0.04 pg/ml, P < 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8301927     DOI: 10.1038/ki.1993.377

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

1.  Oral pulse therapy with vitamin D3 for control of secondary hyperparathyroidism.

Authors:  S Feinstein; N Algur; A Drukker
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

2.  The management of renal osteodystrophy.

Authors:  I B Salusky; W G Goodman
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

3.  MEPE has the properties of an osteoblastic phosphatonin and minhibin.

Authors:  P S N Rowe; Y Kumagai; G Gutierrez; I R Garrett; R Blacher; D Rosen; J Cundy; S Navvab; D Chen; M K Drezner; L D Quarles; G R Mundy
Journal:  Bone       Date:  2004-02       Impact factor: 4.398

Review 4.  Calcitriol administration in end-stage renal disease: intravenous or oral?

Authors:  L D Quarles; O S Indridason
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

5.  Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia.

Authors:  H Funahashi; Y Tanaka; T Imai; M Wada; K Tsukamura; Y Hayakawa; N Matsuura; T Kikumori; M Oiwa; Y Tominaga; H Takagi
Journal:  J Endocrinol Invest       Date:  1998-01       Impact factor: 4.256

Review 6.  Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease.

Authors:  Joao F de Brito Galvao; Larry A Nagode; Patricia A Schenck; Dennis J Chew
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2013 Mar-Apr

7.  Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth.

Authors:  Masatomo Taniguchi; Masanori Tokumoto; Kazuhiko Tsuruya; Hideki Hirakata; Mitsuo Iida
Journal:  Nephrol Dial Transplant       Date:  2008-05-30       Impact factor: 5.992

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.